Xtl Biopharmaceuticals (XTLB) FCF Margin (2011 - 2024)

Xtl Biopharmaceuticals (XTLB) posted quarterly FCF Margin of 104.84% for Q4 2024, up 33.87% on a QoQ basis from 158.54% in Q3 2014.

Xtl Biopharmaceuticals (XTLB) FCF Margin (2011 - 2024) Analysis & Trends

Xtl Biopharmaceuticals (XTLB) has reported FCF Margin for 5 consecutive years, with 104.84% the latest figure, recorded in Q4 2024.

  • Quarterly FCF Margin changed N/A year-over-year to 104.84% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 13.6% (changed N/A YoY) and the FY2025 annual result came in at 186.7%, up 53349.0% from the prior year.
  • FCF Margin improved to 104.84% in Q4 2024 per XTLB's latest filing, from 158.54% in the prior quarter.
  • Over the last five years, FCF Margin for XTLB reached as high as 104.84% in Q4 2024 and fell as low as 104.84% in Q4 2024.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) FCF Margin (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn - -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn 10.45%
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn 43.35%
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn 23.53%
7 Belite Bio 62.72 Bn 62.72 Bn - -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn -
9 Revolution Medicines 37.35 Bn 37.35 Bn - -
10 Xtl Biopharmaceuticals 2.58 Bn 2.58 Bn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 -104.84%
Sep 30, 2014 -158.54%
Jun 30, 2014 -142.11%
Mar 31, 2014 -134.75%
Dec 31, 2013 -62.73%
Sep 30, 2013 -160.25%
Jun 30, 2013 -130.08%
Mar 31, 2013 -80.98%
Dec 31, 2012 -67.90%
Sep 30, 2012 -137.03%
Jun 30, 2012 -61.54%
Mar 31, 2012 -43.72%
Dec 31, 2011 31.20%
Sep 30, 2011 -46.50%
Jun 30, 2011 -41.29%